Sponsored by

Please click on the above banner for more details

WEBSITECHANGES

You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.

Click HERE for details on RSS.

Displaying items 376 to 400 of about 5880

Previous 25

Website Changes

11/29/2022

Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

11/28/2022

Virtual Trials: Causally-validated treatment effects efficiently learned from an observational cancer registry

11/24/2022

Ulixertinib may change childhood brain tumor treatment

11/22/2022

The accelerated approval pathway is evolving in plain sight, with or without congressional help

11/22/2022

Musella Foundation 2022 Highlights

11/22/2022

. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

11/22/2022

The children`s brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science

11/21/2022

DCVAX webinar: Tuesday Nov 29, 2022 at 7pm Eastern

11/19/2022

- Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry

11/19/2022

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

11/19/2022

POSITIVE UPDATED INTERIM RESULTS FROM NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER PRESENTED AT THE SOCIETY FOR NEURO-ONCOLOGY 2022 ANNUAL MEETING

11/19/2022

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

11/17/2022

Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting

11/17/2022

Association of Autologous Tumor Lysate Loaded Dendritic Cell Vaccination With Extended Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

11/17/2022

Vaccine shown to prolong life of patients with aggressive brain cancer

11/16/2022

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

11/16/2022

CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

11/14/2022

Starving Cancer Cells Without Starving You

11/14/2022

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma

11/14/2022

Musella Foundation collaborates with the DIPG/DMG Collaborative to give out $198,436 grant for a low side effect innovative clinical trial for DIPG/DMG

11/14/2022

Giving Tuesday Contest

11/13/2022

Souped-up oncolytic virus warms up cold brain cancer tumors

11/12/2022

Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting

11/11/2022

Alpheus Medical Treats First Patients in First-In-Human Clinical Trial for Novel High-Grade Glioma Brain Cancer Treatment

11/11/2022

Novocure Secures CE Mark for New Array

Our privacy / cookie policy has changed.
Click HERE to read it!